Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Towards clinical development of a Pfs48/45-based transmission blocking malaria vaccine

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. A vaccine targeted specifically to prevent cerebral malaria - is there hope?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The GMZ2 malaria vaccine: from concept to efficacy in humans

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Pre-clinical and clinical development of the first placental malaria vaccine

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. The case for PfEMP1-based vaccines to protect pregnant women against Plasmodium falciparum malaria

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking Vaccine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Malaria is a devastating vector-borne disease caused by the Plasmodium parasite, resulting in almost 0.5 million casualties per year. The parasite has a complex life-cycle that includes asexual replication in human red blood cells, causing symptomatic malaria, and sexual stages which are essential for the transmission to the mosquito vector. A vaccine targeting the sexual stages of the parasite and thus blocking transmission will be instrumental for the eradication of malaria. One of the leading transmission blocking vaccine candidates is the sexual stage antigen Pfs48/45. Areas covered: PubMed was searched to review the progress and future prospects for clinical development of a Pfs48/45-based subunit vaccine. We will focus on biological function, naturally acquired immunity, functional activity of specific antibodies, sequence diversity, production of recombinant protein and preclinical studies. Expert commentary: Pfs48/45 is one of the lead-candidates for a transmission blocking vaccine and should be further explored in clinical trials.

OriginalsprogEngelsk
TidsskriftExpert Review of Vaccines
Vol/bind16
Udgave nummer4
Sider (fra-til)329-336
Antal sider8
ISSN1476-0584
DOI
StatusUdgivet - apr. 2017

ID: 52821748